PharmaCyte Biotech Overview
- Year Founded
-
1996
- Status
-
Public
- Employees
-
2
- Stock Symbol
-
PMCB
- Investments
-
7
- Share Price
-
$7.95
- (As of Thursday Closing)
PharmaCyte Biotech General Information
Description
PharmaCyte Biotech Inc is a biotechnology company focused on developing cellular therapies for cancer based on its proprietary cellulose-based live cell encapsulation technology, Cell-in-a-Box. The technology is intended to be used as a platform for therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC). The current generation of the Company's product candidate is CypCaps. The Company is preparing to commercialize cellular therapies for cancer and advance clinical research and development, including a clinical trial in LAPC using encapsulated live cells. Its candidate therapy involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active, cancer-killing form.
Contact Information
Website
www.pharmacyte.comCorporate Office
- 3960 Howard Hughes Parkway
- Suite 500
- Las Vegas, NV 89169
- United States
Corporate Office
- 3960 Howard Hughes Parkway
- Suite 500
- Las Vegas, NV 89169
- United States
PharmaCyte Biotech Timeline
PharmaCyte Biotech Stock Performance
As of 12-Nov-2026, PharmaCyte Biotech’s stock price is $7.95. Its current market cap is $4.32M with 565K shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $7.95 | $7.58 | $4.69 - $28.69 | $4.32M | 565K | 11.7K | -$43.89 |
PharmaCyte Biotech Financials Summary
As of 31-Jul-2026, PharmaCyte Biotech has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 31-Jul-2026 | FY 2026 30-Apr-2026 | FY 2025 30-Apr-2025 | FY 2024 30-Apr-2024 |
|---|---|---|---|---|
| EV | (29,630) | (11,914) | (8,245) | (25,770) |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (16,828) | (20,158) | 29,240 | (3,065) |
| Net Income | (16,146) | (19,425) | 30,656 | 334 |
| Total Assets | 36,712 | 46,753 | 55,168 | 59,904 |
| Total Debt | 0 | 0 | 0 | 0 |
PharmaCyte Biotech Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
PharmaCyte Biotech Comparisons
Industry
Financing
Details
PharmaCyte Biotech Competitors (61)
One of PharmaCyte Biotech’s 61 competitors is Genetix Biotherapeutics, a Private Equity-Backed company based in Somerville, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Genetix Biotherapeutics | Private Equity-Backed | Somerville, MA | ||||
| TScan Therapeutics | Formerly VC-backed | Waltham, MA | ||||
| Xenetic Biosciences | Corporation | Framingham, MA | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| JW Therapeutics | Formerly VC-backed | Shanghai, China |
PharmaCyte Biotech Patents
PharmaCyte Biotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2018239428-A1 | Encapsulated cells producing cytochrome p450 and methods of use thereof | Inactive | 21-Mar-2017 | ||
| EP-3600261-A1 | Encapsulated cells producing cytochrome p450 and methods of use thereof | Inactive | 21-Mar-2017 | ||
| EP-3600261-A4 | Encapsulated cells producing cytochrome p450 and methods of use thereof | Inactive | 21-Mar-2017 | ||
| US-20180271794-A1 | Encapsulated cells producing cytochrome p450 and methods of use thereof | Inactive | 21-Mar-2017 | ||
| US-20210346304-A1 | Encapsulated cells producing cytochrome p450 and methods of use thereof | Inactive | 21-Mar-2017 | A61K9/5042 |
PharmaCyte Biotech Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
PharmaCyte Biotech Investments & Acquisitions (7)
PharmaCyte Biotech’s most recent deal was a PIPE with Q/C Technologies for . The deal was made on 04-Sep-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Q/C Technologies | 04-Sep-2025 | PIPE | Drug Discovery | ||
| Q/C Technologies | 22-May-2024 | PIPE | Drug Discovery | ||
| Femasys | 15-Nov-2023 | PIPE | Biotechnology | ||
| Austrianova (Cell-in-a-Box) | 06-Sep-2017 | Corporate Asset Purchase | Buildings and Property | ||
| Bio Blue Bird | 01-Jun-2013 | Merger/Acquisition | Other Commercial Products |
PharmaCyte Biotech ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
33.35 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
PharmaCyte Biotech Exits (1)
PharmaCyte Biotech’s most recent exit was on 01-Jun-2013 from Bio Blue Bird. The exit was categorized as with 2 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Bio Blue Bird | 01-Jun-2013 | Completed |
|
PharmaCyte Biotech FAQs
-
When was PharmaCyte Biotech founded?
PharmaCyte Biotech was founded in 1996.
-
Where is PharmaCyte Biotech headquartered?
PharmaCyte Biotech is headquartered in Las Vegas, NV.
-
What is the size of PharmaCyte Biotech?
PharmaCyte Biotech has 2 total employees.
-
What industry is PharmaCyte Biotech in?
PharmaCyte Biotech’s primary industry is Biotechnology.
-
Is PharmaCyte Biotech a private or public company?
PharmaCyte Biotech is a Public company.
-
What is PharmaCyte Biotech’s stock symbol?
The ticker symbol for PharmaCyte Biotech is PMCB.
-
What is the current stock price of PharmaCyte Biotech?
As of 12-Nov-2026 the stock price of PharmaCyte Biotech is $7.95.
-
What is the current market cap of PharmaCyte Biotech?
The current market capitalization of PharmaCyte Biotech is $4.32M.
-
Who are PharmaCyte Biotech’s competitors?
Genetix Biotherapeutics, TScan Therapeutics, Xenetic Biosciences, Adaptimmune Therapeutics, and JW Therapeutics are some of the 61 competitors of PharmaCyte Biotech.
-
What is PharmaCyte Biotech’s annual earnings per share (EPS)?
PharmaCyte Biotech’s EPS for 12 months was -$43.89.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
